Cross-sectional analysis of pneumococcal conjugate vaccine immunity in infants from the community

Clicks: 18
ID: 333552
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #88 of 152 articles by views in turkish journal of public health

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 152 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Pneumococcal conjugate vaccines (PCV) reduce invasive disease and routine pediatric infections, yet subtherapeutic antibody responses have been reported in children with refractory otolaryngologic disease. This study evaluated pneumococcal antibody responses in a community cohort of vaccinated children and compared findings with prior specialty cohorts and prelicensure trial data. Methods Serum from children aged 15–36 months with a documented four-dose PCV series was analysed for IgG concentrations to 14 serotypes. Protective thresholds were defined for invasive disease (≥0.35 μg/ml) and noninvasive disease (≥1.3 and ≥ 2.0 μg/ml). Results were compared with published pediatric cohorts and prelicensure trial data. Results Overall, 77.1% of children met the invasive disease threshold. Only 31.3% and 18.8% met the ≥1.3 and ≥ 2.0 μg/ml thresholds, respectively. Antibody levels were consistently lower than those reported in prior cohorts and prelicensure trials across most serotypes. Conclusions These findings suggest that real-world immunogenicity following routine PCV may differ from that observed in strictly defined and controlled clinical trial populations, particularly at higher antibody thresholds associated with noninvasive disease. Larger-scale, prospective studies are needed to determine if trends hold across broader cohorts.
Reference Key
openalex_W7223271949 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ajay Bharathan, Adele Karen Evans
Are you one of these authors? Claim your profile
Journal turkish journal of public health
Year 2026
DOI
10.1093/pubmed/fdag081
URL
https://doi.org/10.1093/pubmed/fdag081
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.